Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/humupd/dmn039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
mTOR signaling mediates energy metabolic equilibrium in bovine and mouse oocytes during the ovulatory phase†.
Biol Reprod
January 2025
Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction of Ministry of Education, National Center for International Research on Animal Genetics, Breeding and Reproduction, College of Animal Sciences and Technology/Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.
The mammalian target of rapamycin (mTOR) signaling pathway is activated by luteinizing hormone in preovulatory follicle. However, its impact on ovulation remains inadequately explored. Utilizing in vivo studies and in vitro fertilization, we demonstrated that the negative effect of inhibition of mTOR signaling by rapamycin on oocyte quality during the ovulatory phase, with a notable decrease in the total cell count of blastocysts, a reduction in gastrula size, and fetal degeneration on the 16th day of gestation while not affecting ovulated oocyte count or granulosa cell luteinization.
View Article and Find Full Text PDFGonadotropin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction.
Cochrane Database Syst Rev
January 2025
Institute of Education in Healthcare and Medical Sciences, University of Aberdeen, Aberdeen, UK.
Background: Gonadotropin-releasing hormone agonists (GnRHa) are commonly used in assisted reproduction technology (ART) cycles to prevent a luteinising hormone (LH) surge during controlled ovarian hyperstimulation (COH) prior to planned oocyte retrieval, thus optimising the chances of live birth. We compared the benefits and risks of the different GnRHa protocols used.
Objectives: To evaluate the effectiveness and safety of different GnRHa protocols used as adjuncts to COH in women undergoing ART.
The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study.
F S Rep
December 2024
Department of Embryology, Newlife Fertility Centre, Mississauga, Ontario, Canada.
Objective: To compare in vitro fertilization treatment outcomes for the oral gonadotropin-releasing hormone (GnRH) antagonist elagolix (E) to the conventionally used injectable GnRH antagonist ganirelix (G) for achieving pituitary gonadotropin suppression during a controlled ovarian stimulation (COS) cycle.
Design: Retrospective cohort study.
Setting: Private university-affiliated fertility center.
Elagolix for ovulation suppression in in vitro fertilization: Is it time to switch from the painful costly injectables?
F S Rep
December 2024
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Maimonides Medical Center, Brooklyn, New York.
Recent Trends in Medical Management of Endometriosis.
J Obstet Gynaecol India
December 2024
Nowrosjee Wadia Maternity Hospital, Mumbai, India.
Endometriosis affects about 10 percent women in the reproductive age group globally and approximately 42 million in India. Managing the patient's pain symptoms associated with endometriosis appears to be the cornerstone in endometriosis disease management. The ideal medical treatment in endometriosis would be suppressing estradiol enough to alleviate symptoms of endometriosis but maintain sufficient levels to mitigate hypoestrogenic side effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!